Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 3,752 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Completed Phase 2 Interventional Results available

AFQ056 for Language Learning in Children With FXS

NCT02920892
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
AFQ056, Placebo, Language Intervention
Drug · Other
Lead sponsor
Elizabeth Berry-Kravis
Other
Eligibility
32 Months to 6 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
14
States / cities
Davis, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 24, 2026, 9:18 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Head & Neck Cancer With Chemotherapy and Radiation

NCT00392704
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Bevacizumab, Erlotinib, Paclitaxel, 5-FU, Radiation Therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
7
States / cities
Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 24, 2026, 9:18 PM EDT
Terminated Phase 2 Interventional Results available

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

NCT01183884
View directory record Official record
Conditions
Neuroblastoma
Interventions
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Months and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 24, 2026, 9:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT06710847
View directory record Official record
Conditions
Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
Interventions
GSK4418959, PD-1 inhibitor
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 24, 2026, 9:18 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

NCT06053658
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Tivozanib, Nivolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Irvine, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 9:18 PM EDT
Terminated Phase 1 Interventional

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

NCT06700811
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
Interventions
Ketogenic diet
Drug
Lead sponsor
Heather Olson
Other
Eligibility
0 Days to 9 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 9:18 PM EDT
Completed Phase 1 Interventional

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

NCT04422899
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
AIV007
Drug
Lead sponsor
AiViva BioPharma, Inc.
Industry
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Huntington Beach, California • Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 24, 2026, 9:18 PM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 9:18 PM EDT
Completed Phase 3 Interventional Results available

Negative Pressure Wound Therapy in Post-Operative Incision Management

NCT02682316
View directory record Official record
Conditions
Negative-Pressure Wound Therapy
Interventions
dry gauze, The Prevena Incision Management System
Other · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 24, 2026, 9:18 PM EDT
Terminated Not applicable Interventional Results available

Just-In-Time Adaptive Interventions for Addictive Behaviors

NCT03538652
View directory record Official record
Conditions
Addiction
Interventions
Formative Interviews (not an intervention), Cognitive-behavioral therapy (CBT), Acceptance and commitment therapy (ACT), No intervention
Other · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 24, 2026, 9:18 PM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

NCT03656926
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, Standard of Care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 24, 2026, 9:18 PM EDT
Completed Phase 1 Interventional Results available

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

NCT01425008
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma, Solid Tumor, Neoplasm
Interventions
MLN2480
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 24, 2026, 9:18 PM EDT
Completed Early Phase 1 Interventional

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

NCT03295240
View directory record Official record
Conditions
Mantle Cell Lymphoma, Lymphoma
Interventions
BR-I (bendamustine, rituximab, ibrutinib), VEN (Venetoclax)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 24, 2026, 9:18 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

NCT07081997
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm
Combination Product
Lead sponsor
Ascendis Pharma Bone Diseases A/S
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Greeley, Colorado • Chicago, Illinois • Minneota, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 9:18 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00640185
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Lafayette, California • Jacksonville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 24, 2026, 9:18 PM EDT
Terminated Phase 2 Interventional Results available

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

NCT03514017
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Pembrolizumab, Ibrutinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 24, 2026, 9:18 PM EDT
Recruiting Phase 2 Interventional

Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)

NCT05337618
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Full-band Electrocorticography, Treatment Algorithm
Diagnostic Test · Combination Product
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 24, 2026, 9:18 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy

NCT00925938
View directory record Official record
Conditions
Cervical Priming
Interventions
misoprostol, placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 24, 2026, 9:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Impact of the Family Room App on Caregivers

NCT06463158
View directory record Official record
Conditions
Well-Being, Psychological, Engagement, Satisfaction, Consumer
Interventions
Family Room Application
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 24, 2026, 9:18 PM EDT
Completed Phase 2 Interventional Results available

A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

NCT02576678
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 24, 2026, 9:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol

NCT01230515
View directory record Official record
Conditions
Cancer Pain
Interventions
Individual patient interview, focus group and structured survey, interview, focus group and structured survey
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 24, 2026, 9:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin

NCT04231435
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fedratinib, Digoxin, Rosuvastatin, Metformin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 24, 2026, 9:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT

NCT05739643
View directory record Official record
Conditions
Krabbe Disease
Interventions
FBX-101
Biological
Lead sponsor
Forge Biologics, Inc
Industry
Eligibility
Up to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Orange, California • Ann Arbor, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 24, 2026, 9:18 PM EDT
Recruiting Phase 2 Interventional

A Study of Ivonescimab in People With Leiomyosarcoma

NCT07516925
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Ivonescimab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 9:18 PM EDT